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Comparison of Survival and Recurrence Pattern Between
Two-Field and Three-Field Lymph Node Dissections for
Upper Thoracic Esophageal Squamous Cell Carcinoma
Young Mog Shim, MD, Hong Kwan Kim, MD, and Kwhanmien Kim, MD
Introduction: It is controversial to routinely perform three-field
lymph node dissection in patients with upper thoracic esophageal
carcinoma. The objective of this study was to compare survival and
recurrence according to the extent of lymph node dissection in
patients with upper thoracic esophageal squamous cell cancer.
Methods: Between 1995 and 2007, 91 patients underwent R0
esophagectomy (with no residual tumor) for squamous cell carci-
noma of the upper thoracic esophagus at our institution. Of these, 57
patients received three-field (cervical, mediastinal, and abdominal
stations) lymph node dissection (3 FL group), whereas 34 received
two-field (mediastinal and abdominal stations) lymph node dissec-
tion (2 FL group). We retrospectively compared the early and late
postoperative outcomes between the two groups.
Results: No differences were observed between the two groups with
regard to age, gender, and pathologic stage. There was no in-hospital
mortality in either group. The 5-year survival rate was 52% for the
2 FL group and 44% for the 3 FL group (p 0.65). The disease-free
5-year survival rate was 39% for the 2 FL group and 38% for the 3
FL group (p  0.97). The overall recurrence rate and the incidence
of cervical nodal recurrence were not significantly different between
the two groups.
Conclusions: Our findings suggest that there was no survival benefit
from the addition of cervical nodal dissection in patients with upper
thoracic esophageal squamous cell carcinoma who had no evidence
of cervical lymph node metastasis.
Key Words: Esophageal squamous cell carcinoma, Lymph node
dissection, Survival, Recurrence.
(J Thorac Oncol. 2010;5: 707–712)
Lymph node metastasis is one of the most important prog-nostic factors for both locoregional and systemic recur-
rence after complete tumor resection in patients with esoph-
ageal cancer.1,2 Many patients undergoing surgery for
esophageal cancer have positive lymph nodes because of
extensive submucosal lymphatic drainage of the esophagus.3
Therefore, proper lymph node dissection is important for the
treatment of esophageal cancer. However, there is still con-
troversy over the optimal extent of lymph node dissection; that
is, two-field (mediastinal and abdominal stations) versus three-
field (cervical, mediastinal, and abdominal stations) lymph node
dissections.
Many authors have suggested that three-field lymph
node dissection should be performed to determine staging
more accurately, to improve local control, and to enhance
long-term survival, especially in patients with upper thoracic
esophageal cancer.4–6 There is no doubt that the three-field
lymph node dissection can guarantee accurate staging, but
whether it truly improves local control and enhances survival
is still unclear. Given this uncertain survival benefit, it might
not be reasonable to routinely perform three-field lymph node
dissection in the face of serious morbidities such as recurrent
laryngeal nerve palsy.
For patients with upper thoracic esophageal cancer, we
have routinely performed three-field lymph node dissection at
our institution, whereas two-field lymph node dissection has
been pursued for those with middle and lower thoracic
esophageal cancer. However, when patients with upper tho-
racic esophageal cancer were found to have no cervical nodal
metastasis on preoperative imaging studies, we have chosen
not to perform the cervical nodal dissection in selected cases.
The objectives of this study were to (1) compare early and
late postoperative outcomes based on the extent of lymph
node dissection in patients with upper thoracic esophageal
squamous cell carcinoma and (2) determine whether the
extent of lymph node dissection would influence their short-
and long-term results.
PATIENTS AND METHODS
Between September 1994 and December 2007, 124
patients underwent esophagectomy for upper thoracic esoph-
ageal cancer at our institution. Upper thoracic esophageal
cancer was defined as a tumor located between the thoracic
inlet and the tracheal bifurcation. Patients were excluded
when there was residual tumor because of incomplete resec-
tion (n  26) or the histology of the tumor was other than
squamous cell carcinoma (n 5). Therefore, 91 patients were
included in the study population. For patients with upper
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thoracic esophageal cancer, we have routinely performed
three-field lymph node dissection. All patients underwent
computed tomography (CT) and positron emission tomogra-
phy (PET) scans for preoperative staging workup. Since June
2003, we have routinely performed integrated PET/CT scans.
When preoperative CT, PET, or PET/CT scans suggested
cervical nodal metastasis, we tried to do a histologic confir-
mation by ultrasound-guided needle aspiration whenever pos-
sible. However, when patients were found to have no cervical
nodal metastasis on both CT and PET/CT scans, we have
selectively chosen not to perform the cervical nodal dissec-
tion. Among patients who underwent neoadjuvant therapy
because of cervical nodal metastasis, only those who
achieved radiologically complete remission in the cervical
nodal stations received two-field lymph node dissection in
selected cases. Therefore, 34 patients underwent two-field
lymph node dissection (2 FL group), whereas 57 patients
underwent three-field lymph node dissection (3 FL group).
Medical records were retrospectively reviewed to compare
the clinical characteristics and the early and late postoperative
results between the two groups. The study was reviewed and
approved by the Institutional Review Board of Samsung
Medical Center.
Two-field lymph node dissection was defined as the
resection of lymph nodes within the mediastinal and abdom-
inal lymph node stations. The paraesophageal nodes, bilateral
intrathoracic recurrent laryngeal nerve chain nodes, subaortic
arch nodes, subcarinal nodes, and bilateral pulmonary hilar
nodes were dissected through a right thoracotomy. In partic-
ular, bilateral recurrent laryngeal nerves were carefully ex-
posed, and the lymph nodes along these nerves were removed
completely. The paracardiac node, celiac nodes, nodes along
the left gastric artery, and common hepatic artery nodes were
dissected through an upper midline laparotomy. Three-field
lymph node dissection was defined as the resection of lymph
nodes within the cervical lymph node station in addition to the
two above-mentioned lymph node stations. The cervical recur-
rent laryngeal nerve chain nodes and internal jugular nodes
below the level of the cricoid cartilage, supraclavicular nodes,
deep cervical nodes, and cervical paraesophageal nodes were
dissected bilaterally through a cervical collar incision. After
the mobilized stomach was pulled up to either the chest or the
neck through the posterior mediastinal route, an anastomosis
was performed between the stomach and the esophagus. The
anastomosis was located on the left side of the neck in all
patients of 3 FL group. In the 2 FL group, the anastomosis
was located on the left side of the neck in 23 patients (68%),
whereas it was located just below the thoracic inlet in 11
patients (32%). The anastomosis was fashioned in a single
layer using handsewn techniques in patients undergoing a
cervical anastomosis, whereas it was stapled in patients
undergoing intrathoracic anastomosis.
All patients were regularly followed up at intervals of 3
to 4 months for the first 2 years postoperatively, and then
every 6 months thereafter. In those cases lost to follow-up, a
telephone interview was conducted to determine the late
postoperative outcomes. A CT of the chest and upper abdo-
men was performed at every follow-up point, and an upper
endoscopy was conducted annually to rule out the possibility
of disease recurrence. Locoregional recurrence was defined
as that occurring at the anastomoses or at any site within the
previous operative field. When recurrence was detected in the
cervical area of patients undergoing the two-field lymph node
dissection, it was also considered to represent locoregional
recurrence. Distant recurrence was defined as that developing
within a distant solid organ. Whenever recurrence was sus-
pected, we tried to obtain histologic or unequivocal radio-
logic proof.
Descriptive statistics were used to describe patient
characteristics and outcomes. The normally distributed con-
tinuous data were expressed as means SD. Categorical data
were expressed as counts and proportions. Student t tests or
Mann-Whitney U test depending on the normality of distri-
bution and the 2 test or Fisher’s exact test tests were used to
compare the continuous and categorical variables, respec-
tively. Overall survival duration was measured from the date
of surgery until last date of follow-up for patients who
remained alive or until death (including early and late mor-
tality). Disease-free survival was measured from the date of
surgery until first evidence of disease recurrence for patients
who were free of disease. Survival curves were provided
using the Kaplan-Meier method and were compared univari-
ately using the log-rank test. All statistical testing was done at
the two-sided 0.05 level, and Stata software version 10.0
(Stata, College Station, TX) was used.
RESULTS
Patient Profile
The clinical and pathologic characteristics of the study
population are presented in Table 1. The 2 FL group con-
sisted of 31 male patients and three female patients with a
mean age of 60.4  9.9 years. The 3 FL group consisted of
55 male patients and two female patients with a mean age of
61.1  8.1 years. Neoadjuvant treatment (chemotherapy or
radiotherapy or concurrent chemoradiation) was adopted in
10 patients (29%) in the 2 FL group and in 22 patients (39%)
in the 3 FL group. No significant differences were observed
between the 2 FL group and the 3 FL group with regard to
age, gender, or percentage of patients who underwent neoad-
juvant treatment. The mean number of lymph nodes dissected
per patient was 37.8  20.8 in the 2 FL group and 68.7 
29.5 in the 3 FL group. The mean number of metastatic
lymph nodes dissected per patient was 1.7  2.1 in the 2 FL
group and 1.7  2.5 in the 3 FL group. The incidence of
intrathoracic recurrent laryngeal nerve lymph node metastasis
was 35% (12 of 34) in the 2 FL group and 37% (21 of 57) in
the 3 FL group. With respect to the 3 FL group, 11 patients
(19%) had lymph node metastases in the cervical station.
Postsurgical staging was based on the Tumor, Node, Metas-
tasis staging system of the American Joint Committee on
Cancer. There were no significant differences in the incidence
of intrathoracic recurrent laryngeal lymph node metastasis or
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pathologic Tumor, Node, Metastasis stages between the two
groups.
Early Postoperative Outcomes
There was no in-hospital mortality (including death
within 30 days after surgery). Fifteen patients (44%) had
early postoperative complications in the 2 FL group,
whereas 32 (56%) had early postoperative complications in
the 3 FL group (Table 2). The incidence of early postop-
erative complications in the two groups was not signifi-
cantly different. No significant differences were observed
in the incidence of recurrent laryngeal nerve palsy between
the two groups.
Late Follow-Up Outcomes
Follow-up was completed for all the patients, with a
mean duration of 41.8  30.8 months (range, 4.0–135.5
months). There were no significant differences in the fol-
low-up duration between the two groups. At last follow-up,
46 patients were alive with a median survival of 45.6 months
after operation (range, 5.2–135.5 months). The overall 3-year
and 5-year survival rate for all the patients were 63% (95%
confidence interval [CI], 51–72%) and 47% (95% CI, 35–
59%), respectively. The 5-year survival rate for patients who
underwent the two-field lymph node dissection was 52%
(95% CI, 33–68%), compared with 44% (95% CI, 27–59%)
for those who underwent the three-field lymph node dissec-
tion. There were no significant differences in overall survival
between the two groups (p  0.65, Figure 1). The disease-
free 3-year and 5-year survival rate for all the patients were
49% (95% CI, 38–59%) and 38% (95% CI, 27–49%), re-
spectively. The disease-free 5-year survival rate for the 2 FL
group was 39% (95% CI, 21–56%), compared with 38%
(95% CI, 23–52%) for the 3 FL group. There were no
significant differences in disease-free survival between the
two groups (p  0.97, Figure 2).
FIGURE 1. Comparison of overall survival rates between
the 2 FL and 3 FL groups.
TABLE 2. Comparison of the Postoperative Complications
Between the 2 FL and the 3 FL Groups
2 FL 3 FL p
Anastomosis leak 4 9 0.76
Vocal cord palsy 5 16 0.14
Atrial fibrillation 4 3 0.42
Aspiration pneumonia 0 5 0.15
Chylothorax 2 5 0.71
Wound infection 1 1 1.0
2 FL, two-field lymph node dissection group; 3 FL, three-field lymph node
dissection group.
TABLE 1. Clinical and Pathologic Characteristics of the
Study Population
All
Patients
(n  91)
2 FL
(n  34)
3 FL
(n  57) p
Age at operation, yr
(mean  SD)
60.8  8.8 60.4  9.9 61.1  8.1 0.941
Male:female 86:5 31:3 55:2 0.358
Neoadjuvant Tx, n (%) 32 (35) 10 (29) 22 (39) 0.375
Adjuvant Tx, n (%) 31 (34) 12 (35) 19 (33) 0.849
No. of dissected LN 57.4  30.5 37.8  20.8 68.7  29.5 0.000
Number of metastatic LN 1.7  2.3 1.7  2.1 1.7  2.5 0.555
Intrathoracic RLN LN
metastasis, n (%)
classification,
n (%)
33 (36) 12 (35) 21 (37) 0.882
Clinical T stage 0.464
T1 8 (9) 5 (15) 3 (5)
T2 23 (25) 8 (23) 15 (26)
T3 58 (64) 20 (59) 38 (67)
T4 2 (2) 1 (3) 1 (2)
Clinical N stage 0.763
N0 42 (46) 15 (44) 27 (47)
N1 49 (54) 19 (56) 30 (53)
Clinical M stage 0.357
M0 78 (86) 31 (91) 47 (82)
M1a 13 (14) 3 (9)a 10 (18)
Pathologic T stage 0.305
T0 14 (15) 5 (15) 9 (16)
T1 14 (15) 8 (23) 6 (10)
T2 14 (15) 5 (15) 9 (16)
T3 48 (53) 15 (44) 33 (58)
T4 1 (2) 1 (3) 0 (0)
Pathologic N stage 0.725
N0 45 (49) 16 (47) 29 (51)
N1 46 (51) 18 (53) 28 (49)
Pathologic M stage 0.25
M0 77 (85) 31 (91) 46 (81)
M1a 11 (12) 0 (0) 11 (19)
M1b 3 (3) 3 (9)b 0 (0)
a Despite clinical M1a stage, 2-field lymph node dissection was performed in these
patients because they achieved radiologically complete response in the cervical nodal
station following neoadjuvant therapy.
b Reason for M1b staging was celiac lymph node metastasis (n  2) and intraop-
eratively detected liver metastasis, for which hepatic segmentectomy was performed
(n  1).
2 FL, two-field lymph node dissection group; 3 FL, three-field lymph node
dissection group; Tx, therapy; LN, lymph node; RLN, recurrent laryngeal nerve.
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Seventeen patients in the 2 FL group (50%) had recur-
rence during follow-up, whereas 30 in the 3 FL group (53%)
had recurrence. Recurrent disease developing within the cer-
vical lymph node station occurred in three patients in the 2 FL
group and in eight patients in the 3 FL group. The overall
recurrence rate and the incidence of recurrence within the
cervical lymph node station in the two groups were not
significantly different. The pattern of recurrence is listed in
Tables 3 and 4.
Six patients in the 2 FL group (23.1%) had late com-
plications, including anastomosis stricture in four patients,
fistula between the stomach graft and the trachea in one, and
intestinal obstruction in one. Eight patients in the 3 FL group
(20%) had late morbidities; all had anastomosis stricture. No
significant differences in the incidence of late morbidities
were noted between the two groups.
DISCUSSION
Radical esophagectomy combined with three-field
lymph node dissection has been widely adopted by Japanese
surgeons since the early 1980s.4–9 An experimental study
using technetium uptake demonstrated that drainage from the
thoracic esophagus to the bilateral cervical nodal chains
clearly occurs, and this study theoretically justified the addi-
tion of cervical nodal dissection to conventional two-field
lymph node dissection.10 It has been reported that approxi-
mately 30% of patients with middle and lower third esopha-
geal cancer have lymph node metastasis to the neck.4–6
Considering this high incidence of cervical nodal metastasis,
three-field lymph node dissection seems crucial for obtaining
more accurate pathologic staging. In addition, advocates of
the three-field lymph node dissection have argued that this
procedure reduces the rate of locoregional recurrence and
increases long-term survival in patients undergoing esopha-
gectomy. Akiyama et al.,6 in their comparative study, showed
that the survival rate was significantly better in patients who
underwent three-field lymph node dissection compared with
those who underwent two-field lymph node dissection. Al-
torki et al.11 reported that patients who underwent three-field
lymph node dissection had an overall 5-year survival rate of
51%, which was better than that for historical controls.
Despite these favorable results, most of the above-
mentioned studies have critical limitations such as small
sample size, confounding effects of additional nonsurgical
treatment, comparison with historical controls, and retrospec-
tive data collection.3 Although there was one prospective
randomized trial comparing two-field and three-field lymph
node dissection in patients with resectable esophageal cancer,
it also failed to demonstrate any statistically significant dif-
ference in short- and long-term outcomes between the two
groups.12 Furthermore, several studies on recurrence patterns
after two-field lymph node dissection have indicated a much
lower incidence of cervical nodal recurrence than previously
reported.13–15 In our series, cervical nodal recurrence oc-
curred in only three patients (8.8%) and eight patients (14%)
after two-field and three-field lymph node dissections, respec-
tively. In addition, the higher incidence of mediastinal nodal
recurrences and distant organ metastases further limits the
clinical relevance of additional neck dissection. Therefore,
there is no doubt that three-field lymph node dissection can
FIGURE 2. Comparison of disease-free survival rates be-
tween the 2 FL and 3 FL groups.
TABLE 3. Comparison of the Recurrence Pattern After
Esophagectomy Between the 2 FL and the 3 FL Groups
All Patients
(n  91)
2 FL
(n  34)
3 FL
(n  57)
p
Value
Overall recurrence, n (%) 47 (52) 17 (50) 30 (53) 0.808
Locoregional, n (%) 34 (38) 13 (39) 21 (37) 0.810
Distant, n (%) 17 (19) 5 (15) 12 (21) 0.491
L  D, n (%) 5 (6) 2 (6) 3 (5) 1.000
Cervical nodal recurrence,
n (%)
11 (12) 3 (9) 8 (14) 0.528
2 FL, two-field lymph node dissection group; 3 FL, three-field lymph node
dissection group; L, locoregional; D, distant.
TABLE 4. Summary of the Recurrence Site After
Esophagectomy
All Patients
(n  91)
2 FL
(n  34)
3 FL
(n  57)
Locoregional recurrence
Anastomosis site 8 5 3
Cervical lymph node 11 3 8
Mediastinal lymph node 15 5 10
Abdominal lymph node 4 3 1
Pleura 7 4 3
Stomach graft 2 1 1
Tracheobronchial tree 2 1 1
Distant recurrence
Lung 11 4 7
Liver 3 2 1
Brain 2 0 2
Bone 2 0 2
Adrenal gland 1 0 1
2 FL, two-field lymph node dissection group; 3 FL, three-field lymph node
dissection group.
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guarantee accurate staging, but whether it substantially im-
proves local control and enhances survival is still unclear.
Instead, stage migration may explain the improved outcomes
associated with three-field lymph node dissection.3,16
With respect to three-field lymph node dissection, there
are serious concerns over the high incidence of postoperative
morbidities, especially recurrent laryngeal nerve palsy.7 Re-
current laryngeal nerve palsy can lead to lethal complications
such as aspiration pneumonia and also compromise the qual-
ity of life in patients undergoing esophagectomy. Fujita et
al.,17 in their retrospective analysis of optimal lymph node
dissection, reported that 122 of 176 patients who underwent
three-field lymph node dissection (69%) had postoperative
recurrent laryngeal nerve palsy. In our study, although there
was no statistical significance, recurrent laryngeal nerve
palsy occurred in five patients (14.7%) of the 2 FL group
compared with 16 patients (28.1%) of the 3 FL group. This
could also be related to the fact that 8.8% of the patients in
the 3 FL group developed aspiration pneumonia but none
in the 2 FL group.
We compared the early and late postoperative outcomes
between the two-field and three-field lymph node dissection
groups in patients with upper third thoracic esophageal can-
cer. In our study, survival and recurrence pattern of the 2 FL
group were not significantly different to those of the 3 FL
group, although we narrowed down the study population to
patients with squamous cell carcinoma of the upper thoracic
esophagus. Above all, 15% of the study population had
pathologic T0 disease owing to neoadjuvant therapy, and this
may have affected a relatively good survival in this series.
Nonetheless, it is difficult to explain why the outcomes of
two-field lymph node dissection were relatively good in our
series. Although there were no statistically significant differ-
ences in clinical and pathologic stages between the two
groups, it is true that two-field lymph node dissection was
selectively performed for patients with a relatively lower
burden of nodal disease. This intrinsic limitation of nonran-
domized retrospective studies might have had an effect on
favorable outcomes of the 2 FL group. Nonetheless, our
findings raise questions about whether routine cervical nodal
dissection for patients with upper thoracic esophageal cancer
can be justified even when they have little possibilities of
cervical nodal metastasis on preoperative imaging studies. It
should be noted that nine patients who eventually turned out
to have M1a disease despite negative findings on preoperative
imaging studies might benefit from three-field lymph node
dissection. However, 12 patients who were staged patholog-
ically M0 but suffered from vocal cord palsy after three-field
lymph node dissection could have avoided those serious
complications if they had not had the cervical nodal dissec-
tion based on preoperative studies. Three-field lymph node
dissection may signify overtreatment for such patients who
have no evidence of cervical nodal metastasis on imaging
studies. Routinely performing the cervical nodal dissection
just because the tumor is located near the cervical region
seems difficult to be justified.
Our study has several limitations. Because our data
were retrospectively collected and the two-field lymph node
dissection was performed in only selected cases, it is difficult
to draw any decisive conclusions regarding the optimal
lymph node dissection. It might be inappropriate if we tried to
determine what extent of dissection would be adequate in
patients undergoing esophagectomy based solely on this se-
ries. A prospective, randomized controlled trial will be help-
ful in determining what extent of lymph node dissection is
reasonable for patients with esophageal cancer in terms of
survival benefit and risk of serious complications. Further-
more, our study population was rather small, and thus it does
not seem that the power of our suggestions is so strong as to
be conclusive. Despite these limitations, however, our results
suggest that cervical nodal dissection can be omitted in
selected cases, especially for patients who are found to have
no cervical nodal metastasis on preoperative staging workup.
In summary, we compared the early and late postoper-
ative outcomes between esophageal cancer patients undergo-
ing two-field and three-field lymph node dissection. In our
study, short- and long-term outcomes in the two-field lymph
node dissection group were not worse than those in the
three-field lymph node dissection group, even for patients
with upper thoracic esophageal cancer. Three-field lymph
node dissection can be safely performed with excellent early
mortality and acceptable morbidity, but there is no survival
benefit attributable to the addition of cervical nodal dissection
in patients undergoing esophagectomy. We suggest that cer-
vical nodal dissection can be omitted in selected cases,
especially for patients who are found to have no cervical
nodal metastasis on preoperative staging workup.
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